New Lymphoma Drugs Build on BTK Inhibitor Success New Lymphoma Drugs Build on BTK Inhibitor Success

Life expectancy for patients with Waldenstrom ' s macroglobulinemia has improved considerably in the past decade, and new treatments on the horizon could mean that trend continues.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news